retatrutide nonalcoholic steatohepatitis trial Results: 28.3% Weight Loss Data Antifibrotic therapy in nonalcoholic steatohepatitis:

SELECT: Semaglutide Reduces Risk of MACE in Adults with Overweight or Obesity

Lightner, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Dermatologic outcomes: GLP-1 RA versus DPP-4i use The mean follow-up duration was 1,080 454 days in the GLP-1 RA group and 1,121 498 days in the DPP-4i group ( Supplementary Figure 1 )

A waiver of consent was approved because of the retrospective nature of the study with a large number of patients and due to the research involving no more than minimal risk (including privacy risks) to the individuals